Goldman Sachs initiated coverage of JBS (JBS) with a Buy rating and $19.50 price target JBS offers one of the best risk/rewards across global protein stocks, the analyst tells investors in a research note. The firm likes the company’s “highly diversified” portfolio, “consistent execution,” growth algorithm, and “appealing” free cash flow generation. It views the stock’s valuation as “undemanding” at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.